Dual incretin agonists (glucose-dependent insulinotropic polypeptide (GIP) / glucagon - like peptide-1 (GLP-1) receptor agonist) Tirzepatide is the first GIP / GLP1 receptor agonist available for treatment of type 2 diabetes.